Not many dividend stocks can boast the diversification, growth opportunities, and solid balance sheet of health-care company Johnson & Johnson (NYSE:JNJ). With products ranging from consumer goods, like Band-Aids, to cutting-edge drugs for the treatment of prostate cancer, Johnson & Johnson is an attractive stock to dividend investors. In this video, from the Motley Fool's health-care show Market Checkup, analysts David Williamson and Max Macaluso discuss reasons to be bullish about Johnson & Johnson.

The relevant video segment can be found between 7:52 and 9:51.

David Williamson has no position in any stocks mentioned. Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.